| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-06-2473 |
| P698 | PubMed publication ID | 17178895 |
| P50 | author | Susan E. Waltz | Q55324042 |
| P2093 | author name string | Peterson Pathrose | |
| Mike A Leonis | |||
| Margaret H Collins | |||
| Shirelyn R Beauman | |||
| Sarah A Kader | |||
| Glendon M Zinser | |||
| Belinda E Peace | |||
| Kenya Toney | |||
| Megan Thobe | |||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | overexpression | Q61643320 |
| P304 | page(s) | 11967-11974 | |
| P577 | publication date | 2006-12-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation | |
| P478 | volume | 66 |
| Q37412685 | Adhesive and signaling functions of cadherins and catenins in vertebrate development. |
| Q34037017 | Chk2*1100delC Acts in synergy with the Ron receptor tyrosine kinase to accelerate mammary tumorigenesis in mice. |
| Q35986081 | Conditional deletion of β-catenin in mammary epithelial cells of Ron receptor, Mst1r, overexpressing mice alters mammary tumorigenesis. |
| Q47403872 | Delayed Sequential Co-Delivery of Gefitinib and Doxorubicin for Targeted Combination Chemotherapy. |
| Q37079634 | Dietary chemopreventative benzyl isothiocyanate inhibits breast cancer stem cells in vitro and in vivo |
| Q38403475 | Differential expression of RON in small and non-small cell lung cancers |
| Q24304061 | Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer |
| Q35777328 | Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice |
| Q54314075 | Expression and mutational status of RON in neoplastic lesions of the breast: analysis of MSP/RON signaling in ductal carcinoma in situ and invasive ductal carcinoma. |
| Q40081796 | FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells |
| Q36232073 | HGFL supports mammary tumorigenesis by enhancing tumor cell intrinsic survival and influencing macrophage and T-cell responses. |
| Q41708922 | HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β-catenin signaling. |
| Q42700365 | Helioxanthin suppresses the cross talk of COX-2/PGE2 and EGFR/ERK pathway to inhibit Arecoline-induced Oral Cancer Cell (T28) proliferation and blocks tumor growth in xenografted nude mice. |
| Q28593437 | Hepatocyte growth factor-like protein is a positive regulator of early mammary gland ductal morphogenesis |
| Q41814227 | Hepatocyte growth factor-like protein is required for prostate tumor growth in the TRAMP mouse model |
| Q36562072 | Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer |
| Q34518350 | Isolation of Fully Human Antagonistic RON Antibodies Showing Efficient Block of Downstream Signaling and Cell Migration. |
| Q37192507 | KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia |
| Q39882524 | Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma |
| Q38116308 | MSP-RON signalling in cancer: pathogenesis and therapeutic potential |
| Q92987345 | MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages |
| Q33916081 | Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. |
| Q36857449 | Modeling metastatic breast cancer in mice |
| Q36698670 | Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth. |
| Q35213365 | Novel function of transcription factor Nrf2 as an inhibitor of RON tyrosine kinase receptor-mediated cancer cell invasion |
| Q38978586 | Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors |
| Q53591553 | RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers. |
| Q64941091 | RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin. |
| Q42542274 | RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis |
| Q103805894 | RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer |
| Q39869337 | Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells |
| Q40029336 | Regulation of RON tyrosine kinase-mediated invasion of breast cancer cells |
| Q37825724 | Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology |
| Q35577352 | Ron receptor overexpression in the murine prostate induces prostate intraepithelial neoplasia |
| Q34041328 | Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines |
| Q27003295 | Ron receptor tyrosine kinase signaling as a therapeutic target |
| Q37040636 | Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma |
| Q33850098 | Ron-receptor tyrosine kinase in tumorigenesis and metastasis |
| Q47138564 | Sequential delivery of erlotinib and doxorubicin for enhanced triple negative Breast cancer treatment using polymeric nanoparticle. |
| Q35556501 | Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase |
| Q36132585 | Short-form RON overexpression augments benzyl isothiocyanate-induced apoptosis in human breast cancer cells |
| Q38015229 | Strategies for the discovery and development of therapies for metastatic breast cancer |
| Q38922319 | Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery. |
| Q38100162 | Targeted agents in non-small cell lung cancer therapy: What is there on the horizon? |
| Q34765982 | The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers |
| Q37066428 | The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells |
| Q35190869 | The Ron receptor promotes prostate tumor growth in the TRAMP mouse model. |
| Q33783151 | The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer |
| Q42738854 | The Ron receptor tyrosine kinase is not required for adenoma formation in Apc(Min/+) mice |
| Q37308684 | The Ron receptor tyrosine kinase negatively regulates mammary gland branching morphogenesis |
| Q33592512 | The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells |
| Q35758261 | The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans |
| Q35124768 | The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells |
| Q91673432 | Therapeutic Considerations for Ron Receptor Expression in Prostate Cancer |
| Q36140785 | Vitamin D3-dependent VDR signaling delays ron-mediated breast tumorigenesis through suppression of β-catenin activity. |
| Q54546714 | Y654 of β-catenin is essential for FLT3/ITD-related tyrosine phosphorylation and nuclear localization of β-catenin. |
| Q59130211 | mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential |
| Q35100064 | β-Catenin is required for Ron receptor-induced mammary tumorigenesis |
Search more.